It is well accepted that cancer cells have different metabolic programme compared to normal cells [1] . Rapidly replicating tumor cells requirements to support in appropriate cell proliferation and maintain grow this reflected atleast in part by a metabolic shift towards aerobic glycolysis, a phenomenon known as Warburg effect and a modification in gene expression for enzymes involved in other pathways supporting proliferation [2, 3] . Increased glucose uptake lead to modifications of many metabolites mainly associated with cell growth and stress [4, 5] .
Currently, still little is known about the mechanisms linking deregulated metabolism and cancer aggressiveness. Prostate cancer (PCa) is a particularly suitable model to investigate thisaspect. In fact, healthy prostate exhibit a unique metabolism, leading to production of the components of prostatic fluid: PSA, spermine, myso-inositol, and citrate. Such a physiological condition is completely altered in neoplastic cells due to the alteration of glandular frame work, leading to zincloss and subsequently citrate accumulation. Therefore, prostate tumors display unique metabolomic signature [6] .
Sreekumar et al. [7] , analyzed global metabolic profiling of benign and malignant prostate, allowing the creation of a comprehensive catolog of metabolic alterations. Suchanalysis allows not only a better understanding of biological basis of tumor development and progression, but also a platform for the identification of metabolites such as sarcosine, uracil, kynurenine, glycerol-3-phosphate, leucine and proline, which increase with disease progression and may represent new diagnostic and prognostic biomarkers. Metabolomic analysis of biological fluids are minimally invasive and easily accessible, providing a potential useful tool for cancer diagnosis and prognosis. Previously reports indicated citrate, myo-inositol and the polyamine spermine as metabolic markers of PCa in prostatic secretions [8] and metabolic differences between PCa patients and healthy subjects blood samples [9, 10] also of metastasis and recurrence [12] . Unfortunately,both of the tracers were not able to reveal small metastatic sites [13] .
Of note, the study of altered metabolic pathway in pros- vestigation for the identification of new diagnostic and therapeutic strategies in prostate cancer (Figure 1) . Particularly, worthy of attention seems to be fatty acid metabolism studies, potentially able to provide in future useful tools for personalized medicine.
